HilleVax (NASDAQ:HLVX) Issues Earnings Results

HilleVax (NASDAQ:HLVX) released its quarterly earnings results on Friday. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.02), Zacks reports.

HilleVax Trading Down 1.2 %

HilleVax stock opened at $1.59 on Friday. HilleVax has a 52 week low of $1.55 and a 52 week high of $16.66. The stock has a market cap of $79.19 million, a price-to-earnings ratio of -0.51 and a beta of 0.76. The company’s 50-day moving average price is $1.82 and its two-hundred day moving average price is $1.86.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.